Genetic Testing
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
Okay, so when we have patients with triple-negative breast cancer, there are different things we can think about, that we can miss. I think something very important is to make sure you, we have germline genetic testing done for all patients with metastatic or early triple-negative breast cancer. And I think for patients with metastatic triple-negative breast cancer, considering sequencing, it's also important as we have, especially here, we have a lot of trials, and we could consider additional lines of therapy if they have targetable mutations.
In this video, Ilana Schlam, MD, MPH, breast medical oncologist at Dana-Farber Cancer Institute, discusses the importance of germline genetic testing and sequencing for those with metastatic or early-stage triple-negative breast cancer.
“We could consider additional lines of therapy if they have targetable mutations,” she said.
